Barrow Hanley Mewhinney & Strauss LLC Decreases Stake in LivaNova PLC (NASDAQ:LIVN)

Barrow Hanley Mewhinney & Strauss LLC lessened its holdings in LivaNova PLC (NASDAQ:LIVN) by 45.1% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,295,190 shares of the company’s stock after selling 1,064,768 shares during the period. Barrow Hanley Mewhinney & Strauss LLC’s holdings in LivaNova were worth $71,002,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Primecap Management Co. CA lifted its holdings in LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after acquiring an additional 44,049 shares during the period. Vanguard Group Inc. raised its stake in shares of LivaNova by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after purchasing an additional 62,480 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of LivaNova by 6.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock worth $64,262,000 after purchasing an additional 74,067 shares during the period. Greenlight Capital Inc. boosted its holdings in shares of LivaNova by 3.5% in the 4th quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock worth $63,605,000 after buying an additional 42,040 shares during the last quarter. Finally, Magnetar Financial LLC grew its position in LivaNova by 24.5% during the first quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after buying an additional 148,178 shares during the period. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Needham & Company LLC lifted their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $55.00 to $66.00 in a report on Tuesday, September 17th. Finally, Stifel Nicolaus raised their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Buy” and an average price target of $70.80.

LivaNova Stock Performance

NASDAQ LIVN opened at $50.75 on Friday. The firm has a market cap of $2.75 billion, a P/E ratio of -84.58 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $48.85 and its 200-day moving average is $53.38. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. Sell-side analysts predict that LivaNova PLC will post 2.58 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.